What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

Lawsuit alleges Unicycive Therapeutics, Inc. made misleading statements to investors from December 29, 2025 to June 29, 2026; lead plaintiff motions are due November 2, 2026 The Law Offices of Frank R. Cruz today announced a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive Therapeutics" or the "Company") (NASDAQ: UNCY ) on behalf of investors who acquired the Company's securities from December 29, 2025 to June 29, 2026. Filed on September 3, 2026, the case is Patel v. Unicycive Therapeutics, Inc. , U.S. District Court for the Northern District of California, Case No. 26-cv-09559. If you lost money on Unicycive Therapeutics, Inc. securities, submit your Unicycive Therapeutics, Inc. loss information by November 2, 2026 to learn about participating in the lawsuit. Unicycive Therapeutics, Inc. class action timeline Class period begins: December 29, 2025 Class period ends: June 29, 2026 Complaint filed: September 3, 2026 Lead plaintiff motion deadline: November 2, 2026 What happened? On June 30, 2026, Unicycive Therapeutics disclosed that the FDA had issued a second Complete Response Letter regarding the Company's resubmitted New Drug Application for its kidney disease therapy, oxylanthanum carbonate, identifying the same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025. The FDA had not yet inspected the third-party manufacturing facility as part of its review of the resubmission, and raised no concerns about the drug's clinical safety or efficacy. On this news, Unicycive's stock price fell $3.01, or 39.1% (with some reports citing declines up to 46%), to close at $4.69 per share on June 30, 2026, thereby injuring investors. What is the Unicycive Therapeutics, Inc. lawsuit about? The Unicycive Therapeutics, Inc. securities lawsuit alleges that, between December 29, 2025 and June 29, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Unicycive Therapeutics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices; (2) as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices; (4) as a result of the foregoing, the regulatory approval of OLC was reasonably likely to be delayed; and (5) as a result, defendants' positive statements about Unicycive Therapeutics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. " According to the complaint filed against Unicycive Therapeutics, Inc., the Company, among other things, did not disclose that the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices. The November 2, 2026 deadline is a key date for Unicycive Therapeutics, Inc. investors who want a voice in how this case moves forward, " said Frank R. Cruz of The Law Offices of Frank R. Cruz. What should Unicycive Therapeutics, Inc. investors do now? The Law Offices of Frank R. Cruz can help Unicycive Therapeutics, Inc. investors evaluate potential claims to recover their losses. Investors who want to serve as lead plaintiff in the Unicycive Therapeutics, Inc. class action must file a motion with the Court by November 2, 2026. For more information, visit the Unicycive Therapeutics, Inc. case page , email [email protected] , or call 310-914-5007. If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. Investors may retain counsel of their choice. Unicycive Therapeutics, Inc. investors who bought during the class period may also take no action and remain absent class members. No class has been certified yet in the Unicycive Therapeutics, Inc. case. Questions and answers about the Unicycive Therapeutics, Inc. lawsuit Who is eligible? Investors who bought Unicycive Therapeutics, Inc. securities between December 29, 2025 and June 29, 2026 and lost money may be class members, and may seek lead plaintiff appointment by November 2, 2026. What does a lead plaintiff do? The lead plaintiff is appointed by the court to represent all class members and direct the Unicycive Therapeutics, Inc. class action. Must I be lead plaintiff to share in a recovery? No, Unicycive Therapeutics, Inc. investors can take no action and remain absent class members. How are attorneys' fees handled? The Law Offices of Frank R. Cruz works on contingency, so investors pay no attorneys' fees unless there is a recovery, and any fees require court approval. About The Law Offices of Frank R. Cruz The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process. Prior results do not guarantee a similar outcome. Related links Unicycive Therapeutics, Inc. case page, The Law Offices of Frank R. Cruz Complaint: Patel v. Unicycive Therapeutics, Inc., U.S. District Court for the Northern District of California press release Unicycive Therapeutics, Inc. SEC filings index, EDGAR The Law Offices of Frank R. Cruz Follow The Law Offices of Frank R. Cruz for updates on Twitter: twitter.com/FRC_LAW This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. SOURCE The Law Offices of Frank R. Cruz, Los Angeles